Arctic Bioscience A/S

OSL • Healthcare • Biotechnology • Quote as of 10/30/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeOSL

Market Capitalization59.3 mln

Float26.94 mln

Earnings Date05/13/2027

Piotroski F-Score

3 / 9

Below average

Beneish M-Score

-2.98

Likely reliable

Relative Strength

26 / 100

Underperforming

Debt / Equity

0.52

Moderate leverage

Pre-Tax Margin

-87%

Severely loss-making

ROE

-22.95

Deeply negative

Business Description

Founded in 2011 and based in Ørsta, Norway, Arctic Bioscience AS develops medicines and health supplements derived from marine sources, with operations spanning Europe, the United States, and Asia Pacific. Its lead product, HRO350, is an oral treatment for mild-to-moderate psoriasis currently in Phase IIb clinical trials. The company also sells consumer health supplements through its ROMEGA brand.

Key Fundamentals

EPS-1.48

ROE-22.95

RPS1.81

ROIC-11.02

ROA-13.93

Interest Cover-2.95

EBITDA, mln-25.44

EV / EBITDA-5.91

EV / EBIT-5.12

Revenue, mln46.17

EV / Revenue3.26

Quote Details

Last 2.20

Change 0 (0%)

Open 2.10

Volume 1,801

Turnover 3,962.2

Average Volume 4,544.95

Financial Ratios

Pre-Tax Profit Margin-87

Leverage Ratio1.86

Current Ratio0.60

Price / Book0.45

Debt / Equity0.52

Price / Sales1.50

Financial Strength

Altman Z-Score0.02

Piotroski F-Score 3 / 9

Beneish M-Score-2.98

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-6.78%	8 / 100
1 Month	-19.41%	6 / 100
2 Months	-32.1%	5 / 100
6 Months	-33.33%	12 / 100
1 Year	-40.86%	12 / 100